MaxCyte, Inc. Q3 FY2025 earnings call

• Financial Performance: Total revenue was $6.8 million, in line with expectations despite timing of instrument orders. Core revenue was $6.4 million, with SPL program-related revenue $0.4 million.
• SPL Partnerships: Signed 4 new strategic platform licenses in 2025, including with Moonlight Bio, Adicet Bio, and Anocca AB. 14 SPL customers have 18 active clinical programs, with 5 anticipated to enter pivotal studies in 6-18 months.
• SeQure DX Integration: Fully integrated, with market validation of technology and long-term opportunity. SeQure DX assay service revenue was ~$248,000 in the quarter.
• Restructuring: 34% global workforce reduction, expected to realize $17M-$19M annualized savings, with $4M-$5M incremental cost reductions in 2026. Savings include non-headcount-related spending cuts in R&D, G&A, and sales/marketing.
• Clinical Progress: Caribou announced positive Phase I data for allogeneic CAR-T programs; second wave of SPL programs advancing toward pivotal studies and BLA submissions.

MaxCyte reported total revenue of $6.8 million in the third quarter of 2025. This included $6.4 million of core revenue and $0.4 million of SPL program-related revenue. Within core revenue, instrument revenue was $1.4 million, license revenue was $1.8 million, and processing assembly (PA) revenue was $2.6 million. SPL program-related revenue in the third quarter was $0.4 million. Core revenue from SPL customers accounted for 53% in the third quarter of 2025, consistent with the prior year quarter.

• Core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of SeQure DX revenue.
• SPL program-related revenue is anticipated to be approximately $5 million in 2025, a risk-adjusted forecast.
• Expect to end 2025 with between $152 million and $155 million in cash equivalents and investments, reflecting near-term cash utilization from restructuring.

• Challenging operating environment with depressed funding for ex vivo therapies and slower commercial adoption than expected.
• Key customers rationalizing programs, creating a drag on growth in the first half of next year.
• Uncertainty around the realization of SPL program-related revenue projections due to clinical and commercial risks of customers.

Q: How does the current biotech environment impact MaxCyte, and is there stabilization?

A: Maher Masoud notes some stabilization, with no customer indicating delays in development or approval processes due to FDA changes or funding. Funding sentiment remains cautious but hopeful for improvement.

Q: What's the assessment of FDA changes and their impact on customer trials?

A: Maher Masoud states no customers have indicated delays in development or approval timelines due to FDA changes; changes mainly affected equipment purchase hesitations, not development timelines.

Q: What's the outlook for SeQure DX ramp and new platform in 2026?

A: Maher Masoud expects a bigger funnel for SeQure DX in 2026 with more bookings. The new platform, in beta testing, is set for commercial launch early 2026 to drive growth.

Q: What's the expectation for SPL pipeline in 2026?

A: Maher Masoud is confident in signing 3-5 new SPLs in 2026, with a strong funnel due to early collaboration with customers through the FAS team.

Q: Any details on CASGEVY royalty contribution and 2026 revenue breakout?

A: Maher Masoud and Douglas Swirsky highlight Vertex's progress with CASGEVY, noting growing cell collections and dosing, with royalty contribution expected to grow as programs advance.

Q: How does revenue timing affect 2025 and 2026?

A: Douglas Swirsky explains revenue timing is a difference, with some SeQure DX revenue bleeding into next quarter, but remaining on track with year-end expectations.

Q: What are key growth KPIs outside of rationalizing customers?

A: Maher Masoud points to stabilization in non-SPL core business (instrument and PA sales), growth in Asia, and SeQure DX funnel buildup as positive KPIs.

Q: What supports SPL cadence into 2026?

A: Maher Masoud states ongoing early collaboration with customers, working with them pre-SPL signing, gives confidence in 3-5 SPL signings next year.

Q: How has SeQure integration affected long-term gross margin profile?

A: Douglas Swirsky notes margins are stable, expecting higher margins in medium/long term as market strengthens and product mix shifts toward higher-end instruments.